Bone Morphogenic Protein-7 (BMP7) und die Niere

Bechtel, Wibke; Zeisberg, M

doi:10.1055/s-0029-1234003

Cited by 4 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are mainly secreted during the embryonic period, play a key role in bone, cartilage, eye, kidney, and cardiovascular system development. BMP-2-3-4-6-7 and osteogenic protein-1 stimulate bone formation [69]. Research has shown that BMP-2-4-6 stimulates the differentiation of osteoblasts in rat and mouse cells and that BMP-2-7 is involved in the differentiation of bone-derived osteoblasts and progenitor cells in human bone marrow [70,71].…”

Section: Bone Morphogenetic Protein-7mentioning

confidence: 99%

Vascular calcification inhibitors and cardiovascular events in peritoneal dialysis patients

Olmaz,

Selen,

Gungor

2023

Ther Apher Dial

View full text Add to dashboard Cite

The prevalence of cardiovascular diseases is high among patients with chronic kidney disease (CKD) and peritoneal dialysis (PD) patients, which increases morbidity and mortality in this population and represents a significant financial burden for both the patients and the healthcare systems. Vascular calcification (VC) is associated with increased morbidity and mortality and VC risk is higher in patients with CKD than in healthy individuals. Calcification inhibitors, compounds that inhibit VC, were discovered as a result of efforts to explain why some patients are spared. It was found that certain proteins (e.g., fetuin‐A, osteopontin, osteoprotegerin, bone morphogenetic protein‐7) inhibit calcification in dialysis patients. In this narrative review, we provide an overview of known calcification inhibitors, describe the relevant regulatory mechanisms, and discuss their relation to VC development in PD patients.

show abstract

Section: Bone Morphogenetic Protein-7mentioning

confidence: 99%

Vascular calcification inhibitors and cardiovascular events in peritoneal dialysis patients

Olmaz,

Selen,

Gungor

2023

Ther Apher Dial

View full text Add to dashboard Cite

show abstract

Bone Morphogenetic Protein-7 (BMP-7)

Bramlage

Müller

2010

Nephrologe

View full text Add to dashboard Cite

Bone Morphogenetic Protein-7 (BMP-7) wurde initial als ein körpereigener knochenbildender Faktor identifiziert [1]. Erst später wurde die große Bedeutung von BMP-7 auch in der Niere nachgewiesen, zunächst tierexperimentell: BMP-7-Knockout-Mäuse verstarben kurz nach der Geburt mit stark dysplastischen Nieren an einem Nierenversagen [2], BMP spielt also schon in der Entwicklung der Nieren eine essenzielle Rolle. In Studien an erwachsenen Tieren konnte [3] eine regenerative Bedeutung von BMP-7 bei den unterschiedlichsten Nierenerkrankungen nachgewiesen werden. Die Regulierung der Aktivität von BMP-7 ist komplex [1] und bisher nur in Teilen verstanden. Vorerst kann sie in fünf Stufen eingeteilt werden (. Abb. 1): 1. BMP-7 wird durch proteolytische Trennung von Signal-und Propeptid aktiviert; 2. Modulation durch extrazelluläre Moleküle, dazu gehören die BMP-7-Antagonisten Gremlin und Noggin sowie Kielin-Chordin-ähnliches-Protein (KCP), das die Aktivität von BMP-7 verstärkt; 3. Bindung von BMP-7 an die Rezeptoren vom Typ I (Alk-2, -3, -6) und vom Typ II; 4. intrazelluläre Aktivierung von Smads, die in drei Untergruppen eingeteilt werden: a) R-Smads (Smad-1, -5, -8), die direkt durch den Rezeptor phosphorylisiert werden, RedaktionO. Witzke, Essen P Smad-1

show abstract

Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients

Güngör

Koçyiğit

Yılmaz

et al. 2017

Seminars in Dialysis

View full text Add to dashboard Cite

Cardiovascular events make up the primary cause of death in hemodialysis patients, and the risk for cardiovascular mortality is significantly increased by vascular calcification, a condition observed frequently in this patient population. The mechanisms underlying the pathogenesis of vascular calcification are complex, and many factors facilitate or hinder the development of calcification. In this review, we first summarize the main factors contributing to the pathogenesis of vascular calcification in patients with end-stage renal disease. We then explore the role of calcification inhibitors in the calcification process, as well as their effect on vascular dysfunction and mortality in hemodialysis patients. | INTRODUCTIONThe prevalence of cardiovascular diseases is high among patients with chronic kidney disease (CKD), 1 which increases morbidity and mortality in this population and represents a significant financial burden for both the patients and the healthcare systems. where it may occur in the intima and media layers of the blood vessels and in the cardiac valves. 12 The prevalence of coronary artery calcification is high among dialysis patients; specifically, some degree of coronary artery calcification is observed in 54%-100% of patients, well above the prevalence in the general population. 13Older age, male sex, long duration of dialysis, diabetes, hypertension, smoking, alcohol consumption, hyperphosphatemia, hypercalcemia,

show abstract

Bone Morphogenic Protein-7 (BMP7) und die Niere

Cited by 4 publications

References 38 publications

Vascular calcification inhibitors and cardiovascular events in peritoneal dialysis patients

Vascular calcification inhibitors and cardiovascular events in peritoneal dialysis patients

Bone Morphogenetic Protein-7 (BMP-7)

Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients

Contact Info

Product

Resources

About